开发与评估基于模拟的算法以优化肌萎缩侧索硬化症临床试验中期分析规划
研究开发了一种基于模拟的算法,整合肌萎缩侧索硬化症(ALS)临床试验成功率的先验知识与早期药物特异性信息,优化中期分析的数量、时机及终止规则。 retrospectively应用于3项研究膈肌起搏或头孢曲松对ALS患者生存疗效的临床试验,优化设计能正确判定无效,提前1.2-19.4个月结束研究(试验时长缩短4.6%-57.7%),并可能减少随机化患者数1.7%-58.1%。
要点
- 基于模拟的算法可优化ALS临床试验中期分析规划。
- 优化设计正确判定无效,提前1.2-19.4个月结束试验。
- 优化设计可能减少随机化患者数1.7%-58.1%。
核心结论
- 算法利用先验知识确定ALS临床试验预期治疗效应不确定性,优化中期分析规划。
- 改进ALS无效性监测可最小化患者暴露于无效或有害治疗,带来显著伦理与效率收益。
研究设计与样本
- 开发基于模拟的算法,整合ALS临床试验成功率先验知识与早期研究药物特异性信息。
- 通过改变中期分析数量、时机及终止决策规则优化中期分析方案。
- 回顾性应用于3项研究膈肌起搏或头孢曲松对ALS患者生存疗效的临床试验。
- 结局与常规中期设计进行比较。
主要发现
- 每项试验评估183-1,351种独特中期分析方案。
- 应用最优设计正确判定无效,本可提前1.2-19.4个月结束所有研究(试验时长缩短4.6%-57.7%)。
- 本可减少随机化患者数1.7%-58.1%。
- 通过模拟展示其他治疗场景的效率。
- 优化中期分析方案在多数场景优于常规中期设计。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Late-phase clinical trials for neurodegenerative diseases have a low probability of success. In this study, we introduce an algorithm that optimizes the planning of interim analyses for clinical trials in amyotrophic lateral sclerosis (ALS) to better use the time and resources available and minimize the exposure of patients to ineffective or harmful drugs. METHODS: A simulation-based algorithm was developed to determine the optimal interim analysis scheme by integrating prior knowledge about the success rate of ALS clinical trials with drug-specific information obtained in early-phase studies. Interim analysis schemes were optimized by varying the number and timing of interim analyses, together with their decision rules about when to stop a trial. The algorithm was applied retrospectively to 3 clinical trials that investigated the efficacy of diaphragm pacing or ceftriaxone on survival in patients with ALS. Outcomes were additionally compared with conventional interim designs. RESULTS: We evaluated 183-1,351 unique interim analysis schemes for each trial. Application of the optimal designs correctly established lack of efficacy, would have concluded all studies 1.2-19.4 months earlier (reduction of 4.6%-57.7% in trial duration), and could have reduced the number of randomized patients by 1.7%-58.1%. By means of simulation, we illustrate the efficiency for other treatment scenarios. The optimized interim analysis schemes outperformed conventional interim designs in most scenarios. DISCUSSION: Our algorithm uses prior knowledge to determine the uncertainty of the expected treatment effect in ALS clinical trials and optimizes the planning of interim analyses. Improving futility monitoring in ALS could minimize the exposure of patients to ineffective or harmful treatments and result in significant ethical and efficiency gains.
引用
- van Unnik JWJ, Nikolakopoulos S, Eijkemans MJC, et al. Development and Evaluation of a Simulation-Based Algorithm to Optimize the Planning of Interim Analyses for Clinical Trials in ALS. Neurology. 2023. PMID: 37085329. doi:10.1212/WNL.0000000000207306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。